Swiss multinational, Lonza Pharma & Biotech, has chosen Chesterford Research Park to expand their UK operations. Lonza will be relocating their Cambridge site operations from Granta Park to Chesterford Research Park in Q1 2020.
Relocating the Cambridge site operations from Granta Park to Chesterford Research Park allows us to continue to expand our operations and services to support our customers. Increased capacity in the Gonville Building will provide laboratory and office space to further advance risk assessment and development of early-stage biotherapeutics and vaccines. The refurbishment programme is already underway and we plan to relocate the Cambridge operations in Q1 2020.
Head of Applied Protein Services (APS)
Lonza Pharma & Biotech
The life sciences company, which provides contract development and manufacturing services to the pharmaceutical and biotech industries, has signed a 15-year lease of the 42,000 sq ft Gonville building, testament to the strength of the biotech industry in the region.
Situated at the heart of the park, the move to Chesterford will enable Lonza to expand its capabilities to support risk assessment and development of early stage biotherapeutics and vaccines. With the market witnessing a growing pipeline of increasingly complex biologic medicines, Lonza is driving new solutions to enable its customers to move quickly and effectively towards treating patients in clinical trials.
This is a significant move for Lonza as a major customer within the cluster. The fact that we have been able to pre-let the Gonville Building is testament not only to the strength of the market, but also to the Park itself. We are seeing significant interest in Chesterford from a number of sources. The Newnham Building for example, which is currently being completely refurbished, has garnered significant interest – so much so that one suite is now confirmed as pre-let to Isomerase, and of the remaining three, two are currently under offer, despite the fact that the building is not due for completion until 2020. Given the intensity of interest in Chesterford Research Park and looking to the future, discussions are already underway to scope Chesterford’s next phase of speculative development.
Head of Savills Cambridge Office
Chesterford Research Park – providing grow on space for businesses to expand
The news of Lonza’s relocation follows the recent announcement that contract research organisation, Isomerase, has secured the first pre-let within the Newnham Building at Chesterford Research Park.
While Lonza are a new arrival to Chesterford Research Park, Isomerase initially moved to the park in 2013. The Newnham Building fills the gap between and start-ups and established life-science companies. It is therefore ideal for occupiers looking for grow-on space, such as Isomerase. The building offers 37,500 sq ft of laboratory, R&D and admin space.
The ideal environment for life science companies
Chesterford Research Park provides an innovative, flexible and future-proofed environment for both established and early-stage pharmaceutical, biotechnology and technology research and development companies. The currently under-construction Newnham building will provide Life Sciences and Healthcare companies with direct access to world-class people, knowledge, funding and collaborative networks, at significantly lower cost than either Cambridge or London can offer.
Companies currently based at Chesterford Research Park include Arecor, AstraZeneca, Cambridge Epigenetix, Charles River Laboratories, Domainex, Isogenica and Isomerase, and now Lonza. To date, more than 350,000 sq ft of laboratory R&D space has been let and occupied. Further phases of construction are proposed to extend the development to approximately 1 million sq ft.
The attractive 250-acre, low-density development is located close to Cambridge and the M11 with London just one hour away by train, ensuring occupiers and visitors enjoy convenient and easy access. London Stansted Airport is just 20 minutes’ drive away.
To find out more about Chesterford Research Park, click here.